Liang Fang1, Li Shen, Yanfen Fang, Yongzhou Hu, Qiaojun He, Bo Yang. 1. Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, #388 Yuhangtang Road, Hangzhou, Zhejiang 310058, China.
Abstract
PURPOSE: 4-(4-Bromopheny1)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide (MZ3) is one of the novel synthesized Combretastatin A-4 analogs. In previous research, we found that MZ3 is a potent and specific compound against leukemia cell lines both in vitro and in vivo. In this paper, our purpose is to investigate the mechanisms of MZ3 induced cell cycle arrest and apoptosis in K562 cells. METHODS: Cytotoxicity was measured by MTT method; apoptosis and cell cycle arrest were measured by flow cytometry. DNA fragmentation was tested by agarose gel electrophoresis. Protein expression was analyzed by western blotting. The polymerization of microtubules in cell was detected through immunofluorescence. RESULTS: MZ3 increases cyclin B1 levels and decreases the expression of cdc2, cdc25C and activation of Wee1. The changes in cdc2, cdc25C and Wee1 coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. MZ3 induces apoptosis in K562 cells, proved by condensed DNA (DAPI stain) and DNA ladder. This apoptosis is related with the activation of caspase-9, caspase-3 and PARP cleavage, both of which are at the downstream of mitochondria. The changes of protein expression of Bcl-2 and Bax confirm the causal relationship between MZ3 and mitochondrial pathway, and the downregulation of AKT, p-AKT and XIAP indicate that the AKT pathway may participate in regulating this apoptosis. Moreover, MZ3 can reduce the soluble tubulin in K562 cells and inhibit microtubule assembly. CONCLUSIONS: MZ3 is a promising antileukemia compound with antimitotic and apoptotic activity that has potential for management of various leukemias.
PURPOSE:4-(4-Bromopheny1)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide (MZ3) is one of the novel synthesized Combretastatin A-4 analogs. In previous research, we found that MZ3 is a potent and specific compound against leukemia cell lines both in vitro and in vivo. In this paper, our purpose is to investigate the mechanisms of MZ3 induced cell cycle arrest and apoptosis in K562 cells. METHODS:Cytotoxicity was measured by MTT method; apoptosis and cell cycle arrest were measured by flow cytometry. DNA fragmentation was tested by agarose gel electrophoresis. Protein expression was analyzed by western blotting. The polymerization of microtubules in cell was detected through immunofluorescence. RESULTS:MZ3 increases cyclin B1 levels and decreases the expression of cdc2, cdc25C and activation of Wee1. The changes in cdc2, cdc25C and Wee1 coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2. MZ3 induces apoptosis in K562 cells, proved by condensed DNA (DAPI stain) and DNA ladder. This apoptosis is related with the activation of caspase-9, caspase-3 and PARP cleavage, both of which are at the downstream of mitochondria. The changes of protein expression of Bcl-2 and Bax confirm the causal relationship between MZ3 and mitochondrial pathway, and the downregulation of AKT, p-AKT and XIAP indicate that the AKT pathway may participate in regulating this apoptosis. Moreover, MZ3 can reduce the soluble tubulin in K562 cells and inhibit microtubule assembly. CONCLUSIONS:MZ3 is a promising antileukemia compound with antimitotic and apoptotic activity that has potential for management of various leukemias.
Authors: S L Gwaltney; H M Imade; K J Barr; Q Li; L Gehrke; R B Credo; R B Warner; J Y Lee; P Kovar; J Wang; M A Nukkala; N A Zielinski; D Frost; S C Ng; H L Sham Journal: Bioorg Med Chem Lett Date: 2001-04-09 Impact factor: 2.823
Authors: Han C Dan; Mei Sun; Satoshi Kaneko; Richard I Feldman; Santo V Nicosia; Hong-Gang Wang; Benjamin K Tsang; Jin Q Cheng Journal: J Biol Chem Date: 2003-11-25 Impact factor: 5.157
Authors: S A Susin; H K Lorenzo; N Zamzami; I Marzo; C Brenner; N Larochette; M C Prévost; P M Alzari; G Kroemer Journal: J Exp Med Date: 1999-01-18 Impact factor: 14.307
Authors: P Marchetti; M Castedo; S A Susin; N Zamzami; T Hirsch; A Macho; A Haeffner; F Hirsch; M Geuskens; G Kroemer Journal: J Exp Med Date: 1996-09-01 Impact factor: 14.307